beta
Trial Radar AI

Let's discuss and explore clinical trials with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as a lead sponsor or collaborator.

Showing clinical trials for Breast Cancer matching location: China.

I can help you find clinical trials in specific locations and provide insights on health conditions and treatments.

With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

57 Results
Top 50 Showing
 
Status (Default)
Not yet Recruiting, Recruiting, Active, Not Recruiting
×
  
Condition
Breast Cancer
×
 
Location
China
×
 
Study Title
Status
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer (OPTIMAL-BC) NCT07095023
Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer NCT06121557
Recruiting
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer NCT05981001
Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer NCT06121570
Recruiting
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer NCT05981014
Recruiting
Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction NCT06319157
Recruiting
Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy NCT06313463
Recruiting
Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial NCT06024187
Recruiting
Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients NCT04320979
Active, not recruiting
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors NCT06286267
Recruiting
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC NCT07040644
Not yet recruiting
Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge NCT05812040
Recruiting
Regional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer NCT07179744
Recruiting
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer NCT04646759
Recruiting
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy NCT06992336
Recruiting
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer NCT06328387
Recruiting
Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment (HARVEST) NCT03829553
Recruiting
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer NCT05159193
Recruiting
Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer NCT07401537
Recruiting
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients NCT02062489
Recruiting
Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer NCT05466786
Recruiting
Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA) NCT03589924
Active, not recruiting
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis) NCT04803539
Recruiting
Aromatherapy in the Treatment of Early Breast Cancer NCT06435104
Not yet recruiting
Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer NCT05797454
Recruiting
Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant Therapy NCT05838001
Recruiting
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer NCT04872985
Active, not recruiting
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer NCT07037199
Recruiting
Pedicled Lateral Chest Wall Lymph-Adipofascial Flap to Prevent Arm Lymphedema After Breast Cancer Surgery (LAF-ALND) NCT07415200
Not yet recruiting
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer (IFANS) NCT06641544
Recruiting
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer NCT05463601
Active, not recruiting
RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer (RIGAIN) NCT04069884
Recruiting
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer NCT04263298
Recruiting
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer NCT06144944
Active, not recruiting
Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial NCT06716073
Recruiting
Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial NCT05165225
Active, not recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer NCT06889688
Active, not recruiting
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer NCT07371910
Active, not recruiting
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC (Apollo) NCT04501523
Recruiting
Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer NCT06001528
Recruiting
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC NCT04172259
Active, not recruiting
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer NCT07358182
Recruiting
The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. NCT06851299
Recruiting
A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i NCT05953350
Recruiting
The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery NCT06425874
Recruiting
Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer NCT07066280
Recruiting
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing NCT06036563
Recruiting
Acupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients NCT07377279
Recruiting
Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer NCT07046195
Active, not recruiting
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab NCT05760612
Recruiting